Patented therapeutic drug delivery strategies for targeting pulmonary diseases

References

• Nokhodchi A, Martin GP, editors.. Pulmonary drug delivery: : Advances and Challenges; 2015. West Sussex UK: John Wiley and Sons.
   Google Scholar
• Martini A, Muggetti L, Warchol MP. Nasal and pulmonary drug delivery systems. Expert Opin Ther Pat. 2005;10(3):315–323.
   Google Scholar
• Sarasija S, Patil J. Pulmonary drug delivery strategies: a concise systematic review. Lung India. 2012;29(1):44–49.
   PubMedGoogle Scholar
• Ross and Wilson. “Anatomy and physiology in health and illness” by Waugh Anne and Grant Allison. 9th ed. Spain:Churchill Livingstone. 2002;239–250.
   Google Scholar
• Siafakas NM, Pride VP, P Vermeire et al. Optimal assessment and management of chronic obstructive pulmonary disease (COPD). Eur Respir J. 1995;8(8):1398–1420. .
   PubMed Web of Science ®Google Scholar
• Sharma R, Saxena D, Dwivedi A, et al. Inhalable Microparticles containing drug combinations to target alveolar microphages for treatment of pulmonary tuberculosis. Pharm Res. 2001;18(10):1405–1410. .
   PubMed Web of Science ®Google Scholar
• Subramanian J, Govindan R. Lung cancer in never smokers: a review. J Clin Oncol. 2007;25(5):561–570.
   PubMed Web of Science ®Google Scholar
• Di Sant’Agnese PA, Davis PB. Research in cystic fibrosis. New Engl J Med. 1976;295(11):597–602.
   PubMed Web of Science ®Google Scholar
• Newman SP. Drug delivery to the lungs: challenges and opportunities. Ther Deliv. 2017;8(8):647–661.
   PubMed Web of Science ®Google Scholar
• Patel B, Gupta N, Ahsan F. Barriers that inhaled particles encounter. In: Dhand R, editor. ISAM textbook of aerosol medicine. Werne (Germany): International Society for Aerosols in Medicine, online publication; 2015. p. 707–727.
   Google Scholar
• Patton JS, Brain JD, Davies LA, et al. The particle has landed – characterizing the fate of inhaled pharmaceuticals. J Aerosol Med Pulm Drug Deliv. 2010;23(S2):S71–S87. .
   PubMedGoogle Scholar
• Cipolla D. Will pulmonary drug delivery for systemic application ever fulfil its rich promise?. Expert Opin Drug Deliv. 2016;13:1337–1340.
   PubMed Web of Science ®Google Scholar
• Sanchis J, Pedersen S. Systematic review of errors in inhaler use: has patient technique improved over time? Chest. 2016;150(2):394–406.
   PubMed Web of Science ®Google Scholar
• Gangurde H, Chordiya MA, Baste NS, et al. Approaches and devices used in pulmonary drug delivery system: a review. Asian J Pharm Res Health Care. 2012;4:11–27.
   Google Scholar
• Yu CP, Xu GB. Predicted deposition of diesel particles in young humans. J Aerosol Sci. 1987;l8(4):419–429.
   Google Scholar
• Yu CP. Exact analysis of aerosol deposition during steady breathing. Powder Technol. 1978;21(1):55–62. .
   Web of Science ®Google Scholar
• Dua K, Malyla V, Singhvi G, et al. Increasing complexity and interactions of oxidative stress in chronic respiratory diseases: an emerging need for novel drug delivery systems. Chem Biol Interact. 2019;299:168–178.
   PubMed Web of Science ®Google Scholar
• Da Silva AL, Cru FF, Rocco PRM, et al. New perspectives in nanotherapeutics for chronic respiratory diseases. Biophys Rev. 2017;9(5):793–803. .
   PubMedGoogle Scholar
• Borlak J, Benita S, Debotton N, et al. The Hebrew University of Jerusalem. Nanoparticles for targeted delivery of active agents to the lung. WO2009121631A2. 2009.
   Google Scholar
• Hulin J, Xin C, Lei X, et al. China Pharmaceutical University. A kind of nanometer formulation and preparation method thereof for pulmonary fibrosis. CN110384681A. 2019.
   Google Scholar
• Rundfeldt C, Steckel H, Rainer Schlichthaar SH. Nanosuspension with antifungal medication to be administered via inhalation with improved impurity profile and safety. US20110190245A1. 2011.
   Google Scholar
• Kost J, Traitel T, Goldbart R, et al. Children’s Hospital Medical Center. A controlled release system for pulmonary delivery of surfactant protein D. WO2016199146A1. 2016.
   Google Scholar
• Zhibin L, Xuefeng Y; Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences. A kind of load medicine black phosphorus chitosan composite nano ball and its preparation method and application. CN110090307A. 2019.
   Google Scholar
• Yu G, Ziying L, Lisheng Z, et al. Fuzhou University. A kind of chitosan nano-material and preparation method thereof for lung cancer therapy. CN110251689A. 2019.
   Google Scholar
• Benoit JP, Dulieu C, Meurlay DL, et al. Microparticles for pulmonary administration. EP1204409A1. 2002.
   Google Scholar
• Tzannis ST, Sadrzadeh N, Schiavone H; Therapeutics. Sustained release microparticles for pulmonary delivery. WO2006124446A2. 2006.
   Google Scholar
• Curtis L; Coselix Ink Cotherix Inc., Treatment with iloprost inhaled using a microparticle formulation of pulmonary hypertension. JP2008507585A. 2008.
   Google Scholar
• Cryan SA, Sivadas N; Royal College of Surgeons In Ireland. Inhalable microparticles and methods for the production thereof. WO2010007604A2. 2010.
   Google Scholar
• Martyn GP; Quadrant Drug Delivery Ltd., Therapeutic compositions for pulmonary distribution. PT1259228E. 2010.
   Google Scholar
• Tingming F, Wenqiang S; Nanjing University of Chinese Medicine. A kind of ‘Xiduofeng’ drug microparticles of pulmonary administration and the preparation method and application thereof. CN109674773A. 2019.
   Google Scholar
• Lee H, Listevsky B, Boylan JC, et al. Derek Ceraputix Corp., Stable liposome compositions comprising lipophilic amine containing pharmaceutical agents. KR20060123341A. 2006.
   Google Scholar
• Takeuti H, Hakaho K, Toyobuku H; Otsuka Pharmaceutical Co. Ltd., Transpulmonary liposome for controlling drug delivery. RU2493874C2. 2013.
   Google Scholar
• Zhiyong Y, Xinyu L, Zhiqin, et al. Long-acting liposome preparation for pulmonary drug delivery and preparation method thereof. CN103784403A. 2014.
   Google Scholar
• Cipolla DC, Gonda I; Aradigm Corp., Inhaled surfactant-modified liposomal formulations providing both an immediate and sustained release profile. US20150110855A1. 2015.
   Google Scholar
• Yiguang J, Mengmeng Z, Lina D; Military Mediccal Research Institute, Chinese Academy of Military Sciences. Paclitaxel-loaded liposome bacterium inhalation preparation for treating lung cancer. CN110559280A. 2019.
   Google Scholar
• Kaihua L, Qian W, Meiling Z Anti-lung cancer Docetaxel active targeting liposome. CN107260678B. 2019.
   Google Scholar
• Weers J; Insmed Inc., Lipid-based compositions of antiinfectives for treating pulmonary infections and methods of use thereof. US9549939B2. 2017.
   Google Scholar
• Bhat MG, Cuff GW, Wolff RK; Eli Lilly and Co., Protein powder for pulmonary delivery. WO2001093837. 2001.
   Google Scholar
• Aldous BJ, Clark A, Kuo M-C, et al. Nektar Therapeutics. Dry powder active agent pulmonary delivery. AU753014B2. 2002
   Google Scholar
• Charan C, Dwivedi S; Bayer HealthCare AG. Antibiotic formulations, unit doses, kits, and methods. US20120247462A1. 2012.
   Google Scholar
• Lipp MM, Sung JC; Pulmatrix Inc., Cationic dry powder. US9433576B2. 2016.
   Google Scholar
• Smutney CC, Adamo B, Laurenzi BF, et al. Dry powder drug delivery system and methods. US9802012B2. 2017
   Google Scholar
• Perry JM, Hava DL, Saunders RC, et al. Pulmatrix Operating Company. Antifungal formulations for pulmonary administration comprising itraconazole. WO2019204583A1. 2019.
   Google Scholar
• Lai J, Kessler DR, Quay SC; Sonus Pharmaceuticals Inc., Emulsions for aerosolization and drug delivery. WO1999024016A1. 1999.
   Google Scholar
• Weirs JG, Knob CA, Sut EG, et al. Inhal Therapeutic Systems Inc., Stabilizing preparations for use in the nebulizer. JP2001517692A. 2001.
   Google Scholar
• Ufer S, Hofmann T; Qrumpharma Inc., Inhalable clofazimine formulation. WO2019110099A1. 2019.
   Google Scholar
• Kreuter J. Nanoparticles–a historical perspective. Int J Pharm. 2007;331(1):1–10.
   PubMed Web of Science ®Google Scholar
• Sung JC, Pulliam BL, Edwards DA. Nanoparticles for drug delivery to the lungs. Trends Biotechnol. 2007;25(12):563–570.
   PubMed Web of Science ®Google Scholar
• Matsuo Y, Ishihara T, Ishizaki J, et al. Effect of betamethasone phosphate loaded polymeric nanoparticles on a murine asthma model. Cell Immunol. 2009;260(1):33–38. .
   PubMed Web of Science ®Google Scholar
• Bhavna, Ahamad FJ, Mittal G et al. Nano-salbutamol dry powder inhalation: A new approach for treating broncho-constrictive conditions. Eur J Pharm Biopharm. 2009;71(2):288–291. .
   Web of Science ®Google Scholar
• Bailey MM, Gorman EM, Munson EJ. Pure insulin nanoparticle agglomerates for pulmonary delivery. Langmuir. 2008;24(23):13614–13620.
   PubMed Web of Science ®Google Scholar
• Sung JC, Padilla DJ, Garcia-Contreras L, et al. Formulation and pharmacokinetics of self-assembled rifampicin nanoparticle systems for pulmonary delivery. Pharm Res. 2009;26(8):1847–1855. .
   PubMed Web of Science ®Google Scholar
• Mastorakos P, Silva ALD, Chisholm J et al. Highly compacted biodegradable DNA nanoparticles capable of overcoming the mucus barrier for inhaled lung gene therapy. Proc Natl Acad Sci USA. 2015;112(28):8720–8725. .
   PubMed Web of Science ®Google Scholar
• Iii ROW, Johnston KP, Sinswat P, et al. The University of Taxes System. Enhanced delivery of immunosuppressive drug compositions for pulmonary delivery. CA3027598A1. 2008.
   Google Scholar
• Alpar HO, Somavarapu S, Atuat KN, et al. Biodegradable mucoadhesive particulates for nasal and pulmonary antigen and DNA delivery. Adv Drug Deliv Rev. 2005;57(3):411–430. .
   PubMed Web of Science ®Google Scholar
• Healy AM, McDonald BF, Tajber L, et al. Characterisation of excipient-free nanoporous microparticles (NPMPs) of bendroflumethiazide. Eur J Pharm Biopharm. 2008;69(3):1182–1186. .
   PubMed Web of Science ®Google Scholar
• Cook RO, Pannu RK, Kellaway IW. Novel sustained release microspheres for pulmonary drug delivery. J Control Release. 2005;104(1):79–90.
   PubMed Web of Science ®Google Scholar
• Fiore VF, Lofton MC, Roser-Page S, et al. Polyketal microparticles for therapeutic delivery to the lung. Biomaterials. 2010;31(5):810–817. .
   PubMed Web of Science ®Google Scholar
• Tewes F, Paluch KJ, Tajber L, et al. Steroid/mucokinetic hybrid nanoporous microparticles for pulmonary drug delivery. Eur J Pharm Biopharm. 2013;85(3):604–613. .
   PubMed Web of Science ®Google Scholar
• Derosa F, Guild BC, Heartlein M, et al. Shire Human Genetics Therapies Inc., Pulmonary delivery of mRNA to non-lung target cells. AU2013271392B2. 2018.
   Google Scholar
• Chimote GC, Mahajan GB, Vasudevan A, et al. Priamal Enterprises Ltd., Microparticle formulation for pulmonary drug delivery of anti-infective molecule for treatment of infectious diseases. US8697653B2. 2014.
   Google Scholar
• Chen X, Huang W, Kwan W, et al. Liposomes prolong the therapeutic effect of anti-asthmatic medication via pulmonary delivery. Int J Nanomedicine. 2012;7:1139–1148.
   PubMed Web of Science ®Google Scholar
• Bi R, Shao W, Wang Q, et al. Spray-freeze-dried dry powder inhalation of insulin-loaded liposomes for enhanced pulmonary delivery. J Drug Target. 2008;16(9):639–648.
   PubMed Web of Science ®Google Scholar
• Huang YY, Wang CH. Pulmonary delivery of insulin by liposomal carriers. J Control Release. 2006;113(1):9–14.
   PubMed Web of Science ®Google Scholar
• Liu FY, Shao Z, Kildsig DO, et al. Pulmonary delivery of free and liposomal insulin. Pharm Res. 1993;10(2):228–232. .
   PubMed Web of Science ®Google Scholar
• Hamedinasab H, Rezayan AH, Mellat M, et al. Development of chitosan coated liposomes for pulmonary delivery of N-acetyl cysteine. Int J Biol Macromol. 2019. (Ahead of print). 10.1016/j.ijbiomac.2019.11.190
   PubMedGoogle Scholar
• Manunta MDI, Tagalakis AD, Attwood M, et al. Delivery of ENaC siRNA to epithelial cells mediated by a targeted nanocomplex: a therapeutic strategy for cystic fibrosis. Sci Rep. 2017;7:1–12.
   PubMed Web of Science ®Google Scholar
• Han O, Zameknik J, Schek PN, et al. Orlando Han., Pulmonary delivery of liposome-encapsulated cannabinoid. JP2003504321A. 2003.
   Google Scholar
• Cipolla DC, Blanchard J; Aradigm Corp., Concentrated, inhalable ciprofloxacin formulation. US9545401B2. 2017.
   Google Scholar
• Kurniawansyah F, Mammucari R, Foster NR. Curcumin powders for pulmonary delivery by supercritical processing. Asian Pac Confederation Chem Eng Congr. 2015;1208–1213.
   Google Scholar
• Mehta P, Bothiraja C, Mahadik K, et al. Phytoconstituent based dry powder inhalers as biomedicine for the management of pulmonary diseases. Biomed Pharmacother. 2018;108:828–837.
   PubMed Web of Science ®Google Scholar
• Irngartinger M, Camuglia V, Damm M, et al. Pulmonary delivery of therapeutic peptides via dry powder inhalation: effects of micronisation and manufacturing. Eur J Pharm Biopharm. 2004;58(1):7–14.
   PubMed Web of Science ®Google Scholar
• Muralidharan P, Hayes D, Black SM, et al. Microparticulate/nanoparticulate powders of a novel Nrf2 activator and an aerosol performance enhancer for pulmonary delivery targeting the lung Nrf2/Keap-1 pathway. Mol Syst Des Eng. 2016;1(1):48–65. .
   PubMed Web of Science ®Google Scholar
• Smutney CC, Leone-Bay A, Galarza JM, et al. TechnoVax Inc., Inhalable vaccine compositions and methods. US20150283069A1. 2015.
   Google Scholar
• Smatni CS, Adamo B, Polidoro JM, et al. Mannkind Corporation. Systems and methods for dry powder drug delivery. RU2571331C1. 2015.
   Google Scholar
• Jadhav KR, Shaikh IM, Ambade KW, et al. Applications of microemulsion based drug delivery system. Curr Drug Deliv. 2006;3(3):267–273. .
   PubMedGoogle Scholar
• Sommerville ML, Cain JB, Johnson Jr CS, et al. Lecithin inverse microemulsions for the pulmonary delivery of polar compounds utilizing dimethylether and propane as propellants. Pharm Dev Technol. 2000;5(2):219–230. .
   PubMed Web of Science ®Google Scholar
• Shah SA, Sandidge JA, Sharp M, et al. Low dose corticosteroid microemulsion compositions and methods of treatments thereof. WO2015009776A1. 2015.
   Google Scholar
• Sanders M. Inhalation therapy: an historical review. Prim Care Respir J. 2007;16(2):71–81.
   PubMedGoogle Scholar
• Davis CC, Colin SD; Hewlett-Packard Company. Thermal formation of drop of aerosol. JP2002248171A. 2002.
   Google Scholar
• Robert MP, Zone SP, poster L, et al. Nectar Therapeutics. Pulmonary delivery of a pharmaceutical aerosol jolhwa. KR100466486B1. 2005.
   Google Scholar
• Busick RD, Dvorsky EJ, Peters DR, et al. Battelle Memorial Institute Inc., Apparatus and methods for delivering respirable aerosol. DE69924018T2. 2006.
   Google Scholar
• Bosch HW, Ostrander KD, Cooper ER; Elan Pharma International Ltd. Dry powder aerosols of nanoparticulate drugs. US7521068B2. 2009.
   Google Scholar
• Atterbury WG, Bouton CE, Busick DR, et al. Nozzle for handheld pulmonary aerosol delivery device. US7849850B2. 2010.
   Google Scholar
• Omura Y, Okazaki T; Tanaka Metal Ind Co Ltd. Mesh for nebulizer and production method thereof. EP2644282B1. 2015.
   Google Scholar
• Morrison MS; Koninklijke Philips NV. System and method for monitoring a metered dose inhaler. US8960189B2. 2015.
   Google Scholar
• Sugianto A; MAP Pharmaceuticals Inc., Dose counter with lockout mechanism. US20170007786A1. 2017.
   Google Scholar
• Howgill SJ; 3M Innovative Properties Co. Dose counter for metered dose inhaler. US20170021117A1. 2017.
   Google Scholar
• King M, Warden JA, Kim J, et al. Nicholas Oxley. Methods of operating dry powder inhalers having spiral travel paths with microcartridges of dry powder. US20110253141A1. 2011.
   Google Scholar
• Villax P, Mendes PJ, McDerment IG; Hovione International Ltd. Simple capsule-based inhaler. US8677992B2. 2014.
   Google Scholar
• Smutney CC, Kinsey PS, Sahi CR, et al. Mannkind Corp. Dry powder inhaler and system for drug delivery. US9192675B2. 2015.
   Google Scholar
• Lugtigheid GW, Inhaleness BV Inhaler, comprising a hydrogen generator. WO2010052323A2. 2010.
   Google Scholar
• Sickle JDV, Tracy G, Hoffman E, et al. Reciprocal Labs Corp. Usage monitoring attachment for a soft mist inhaler. USD757926S1. 2016
   Google Scholar
• Ward ME, Woodhouse A, Mather LE, et al. Morphine pharmacokinetics after pulmonary administration from a novel aerosol delivery system. Clin Pharmacol Ther. 1997;62(6):596–609. .
   PubMed Web of Science ®Google Scholar
• Thorsson L, Edsbacker S, Conradson TB. Lung deposition of budesonide from Turbuhaler is twice that from a pressurized metered-dose inhaler P-MDI. Eur Respir J. 1994;7(10):1839–1844.
   PubMed Web of Science ®Google Scholar
• Germinario LT, Hebrank JH, Hunter CE, et al. Stern TP Inventors. Methods for the systemic delivery of therapeutic agents to the pulmonary system using a droplet delivery device. US20190125986A1. 2019.
   Google Scholar
• Power JS, Moran D, Devery D, et al. Novartis AG. Nebuliser for the production of aerosolized medication. US8616195B2. 2013.
   Google Scholar
• Niven R, Watanabe W, Thomas M, et al. Discovery Laboratories Inc., Methods, systems and devices for noninvasive pulmonary delivery. WO2006026237A1. 2006.
   Google Scholar
• Matera MG, Page C, Rogliani P, et al. Therapeutic monoclonal antibodies for the treatment of chronic obstructive pulmonary disease. Drugs. 2016;76(13):1257–1270. .
   PubMed Web of Science ®Google Scholar
• Sun S, Schiller JH, Spinola M, et al. New molecularly targeted therapies for lung cancer. J Clin Invest. 2007;117(10):2740–2750.
   PubMed Web of Science ®Google Scholar